Factors such as increasing number of research and developments in oncology sector, advancements in drug development, new product launch, and the introduction of various new therapies are leading towards the growth of the global Chronic Myelogenous Leukemia Treatment Market.
Increasing prevalence of chronic myelogenous leukemia in developed countries due to genetic factors is also resulting in the development of new treatment and therapies that are more effective. Researchers are also focusing on polypharmacology approach to develop the drugs that can act on multiple targets. This is leading to the drug discovery opportunities that are beyond the concept of ‘one drug, one target’. The class of drugs known as TKIs is being used on a large scale, however, side-effects of these drugs are affecting its growth. Hence, new drugs and treatments are being developed to run the treatment successfully without any risk. Moreover, the rise in the development of a combination of drug therapies is also fueling the growth of the market.
High-cost of treatment being the biggest factor hampering market growth. Manufacturers are focusing on reducing the cost of TKIs. Meanwhile, the government of various countries are also taking initiatives to provide TKIs to the large section of population who are not able to afford it.
According to the report by Transparency Market Research (TMR), the global market for chronic myelogenous leukemia is likely to witness strong growth, registering 6.7% CAGR during 2017-2026. The market is also estimated to bring in US$ 8,550.8 million revenue by 2026 end.
Request to View Sample of Report -
Disease specific treatment is likely to gain maximum revenue share, accounting for more than three-fourth of the revenue share by 2017 end. Disease specific treatment is also projected to exceed US$ 7,100 million revenue towards 2026 end.
Compared to the other distribution channel, hospital pharmacies are likely to witness significant growth during 2017-2026. By 2026 end, hospital pharmacies are estimated to surpass US$ 4,600 million revenue. Meanwhile, specialty pharmacies are also likely to witness healthy growth between 2017 and 2026. Branded drugs are likely to gain maximum traction in the market during 2017-2026. Branded drugs are estimated to exceed US$ 6,800 million revenue by 2026 end.
Comments
Post a Comment